Observational studyMedicine2025

Consideration of ledipasvir/sofosbuvir as an alternative to glecaprevir/pibrentasvir based upon on-treatment FIB-4 changes and sustained virologic response at 12 weeks in hepatitis C genotype 1 and 2 infections: A propensity score-matched study.

Hyun Joon Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.